Home / Market Update / Pfizer and BioNTech: Vaccine 95% Effective in Final Efficacy Analysis of Phase 3 Trial

Pfizer and BioNTech: Vaccine 95% Effective in Final Efficacy Analysis of Phase 3 Trial

Pfizer Inc said on Wednesday that the final efficacy analysis of phase 3 trial of the coronavirus vaccine it develops with BioNTech has shown to be 95% effective, as reported by Reuters.

“Efficacy of COVID-19 vaccine was consistent across age, race and ethnicity demographics.”

“Planning to file for US emergency use authorization of COVID-19 vaccine within days.”

“Concluded phase 3 study with 170 confirmed cases of covid; 162 of those cases were in the placebo arm.”


Check Also

Sterling Falters Against Yen Amid Tariff Fears and UK Political Strife

The British Pound (GBP) weakened against the Japanese Yen (JPY), with GBP/JPY slipping below 197.61, …